{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(4)"],"submitter":["Lim RS"],"pubmed_abstract":["Immunoglobulin A nephropathy (IgAN) remains the leading cause of primary glomerular disease worldwide. Outcomes are poor with high rates of progressive chronic kidney disease and kidney failure, which contributes to global healthcare costs. Although this disease entity has been described, there were no disease-specific treatments until recently, with the current standard of care focusing on optimal supportive measures including lifestyle modifications and optimization of the renin-angiotensin-aldosterone blockade. However, with significant advances in the understanding of the pathogenesis of IgAN in the past decade, and the acceptance of surrogate outcomes for accelerated drug approval, there have been many new investigational agents tested to target this disease. As these agents become av"],"journal":["Journal of clinical medicine"],"pagination":["947"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10889409"],"repository":["biostudies-literature"],"pubmed_title":["An Update on Current Therapeutic Options in IgA Nephropathy."],"pmcid":["PMC10889409"],"pubmed_authors":["Lim RS","Yeo SC","Barratt J","Rizk DV"],"additional_accession":[]},"is_claimable":false,"name":"An Update on Current Therapeutic Options in IgA Nephropathy.","description":"Immunoglobulin A nephropathy (IgAN) remains the leading cause of primary glomerular disease worldwide. Outcomes are poor with high rates of progressive chronic kidney disease and kidney failure, which contributes to global healthcare costs. Although this disease entity has been described, there were no disease-specific treatments until recently, with the current standard of care focusing on optimal supportive measures including lifestyle modifications and optimization of the renin-angiotensin-aldosterone blockade. However, with significant advances in the understanding of the pathogenesis of IgAN in the past decade, and the acceptance of surrogate outcomes for accelerated drug approval, there have been many new investigational agents tested to target this disease. As these agents become av","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2025-04-22T13:24:21.424Z","creation":"2025-02-19T01:38:49.753Z"},"accession":"S-EPMC10889409","cross_references":{"pubmed":["38398259"],"doi":["10.3390/jcm13040947"]}}